The Proteomics Core Facility makes advanced mass spectrometry instruments, expertise, and methods for protein analysis available to the Case Comprehensive Cancer Center (Case CCC) community. The Core includes two laboratory sites, one on the CWRU campus and one the CCF campus, with a current total of 6,000 sq ft of laboratory space. The Core is directed by Dr. Mark Chance and has a staff of approximately 20 individuals including scientists specializing in mass spectrometry, protein chemistry, instrument engineering, and bioinformatics. A total of 8 mass spectrometry systems are housed in the laboratories, including electrospray and Maldi, and ion trap, ToF, QTof, and FTMS systems. The services that are offered to the Case CCC community are wide-ranging;from a drop-off service for protein identification, to collaborative services for the detection and characterization of post-translation modifications, quantitative proteomics, and protein structural analyses to open instrument access for trained users. Members have used mass spectrometry from the Core, to reveal that the reversible dimethylation on K140 by histone-modifying enzymes occurs only when it is part of a promoter-bound complex. Other members have utilized the Core to identify DNMT1-associated proteins including HAUSP from a series of pull down experiments. In particular, in-solution samples generated from pull down experiments were analyzed by tandem MS. The Core has provided services for Cancer Center members from 7 of the 8 Scientific Research Programs.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research Involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765393
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726

Showing the most recent 10 out of 1227 publications